Please assess the completion status of the following clinical trial:

Trial Title: High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed AML or RAEB~* 15 years of age or older, but younger than 60 years of age~* Adequate hepatic and renal function~* Normal cardiac function with LVEF ≥ 50% on MUGA scan or echocardiogram~* Written informed consent~Exclusion Criteria:~* promyelocytic leukemia or chronic myelogenous leukemia~* significant infection~* prior chemotherapy history for leukemia

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- arm I (Type: ACTIVE_COMPARATOR): Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).